Talk:AB-CHMINACA: Difference between revisions

>Benzofury
m Grammatics
>Unity
m Grammatics
Line 1: Line 1:
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/AB-CHMINACA}}
{{SubstanceBox/AB-CHMINACA}}
Line 55: Line 54:
*'''[[Effect::Auditory enhancement|Enhancements]]'''
*'''[[Effect::Auditory enhancement|Enhancements]]'''
}}
}}
}}
}}
===Experience reports===
===Experience reports===
Line 71: Line 69:
As synthetic cannabinoids are active in the milligram range (with below 1mg being a typical dose for AB-CHMINACA), it is important to [[Dosage|use proper precautions when dosing]] to avoid a negative experience.
As synthetic cannabinoids are active in the milligram range (with below 1mg being a typical dose for AB-CHMINACA), it is important to [[Dosage|use proper precautions when dosing]] to avoid a negative experience.


It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug.
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance.
===Tolerance and addiction potential===
 
===Dependence and abuse potential===
As with other synthetic cannabinoids, the chronic use of AB-CHMINACA can be considered [[Addiction potential::moderately addictive with a high potential for abuse]] and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and [[withdrawal effects]] may occur if a person suddenly stops their usage.
As with other synthetic cannabinoids, the chronic use of AB-CHMINACA can be considered [[Addiction potential::moderately addictive with a high potential for abuse]] and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and [[withdrawal effects]] may occur if a person suddenly stops their usage.


Tolerance to many of the effects of AB-CHMINACA [[Time to full tolerance::develops with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). AB-CHMINACA presents cross-tolerance with [[Cross-tolerance::all [[cannabinoids]]]], meaning that after the consumption of AB-CHMINACA all cannabinoids will have a reduced effect.
Tolerance to many of the effects of AB-CHMINACA [[Time to full tolerance::develops with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). AB-CHMINACA presents cross-tolerance with [[Cross-tolerance::all [[cannabinoids]]]], meaning that after the consumption of AB-CHMINACA all cannabinoids will have a reduced effect.


==Legal issues==
==Legal status==
*'''Brazil''' - As of August 21, 2018, AB-CHMINACA has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.<ref>List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial</ref>
*'''Brazil:''' On August 21, 2018, AB-CHMINACA was added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.<ref>List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial</ref>
*'''United Kingdom''' - AB-CHMINACA is a class B drug under the third-generation synthetic cannabinoids generic definition, which came into effect on the 14th December 2016 and is illegal to possess, produce, supply, or import. <ref>The Misuse of Drugs Act 1971 (Amendment) Order 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2016/1109/made</ref>
*'''China:''' As of October 2015, AB-CHMINACA is a controlled substance in China.<ref>关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref>
*'''USA:''' In January 2015, AB-CHMINACA was designated as a Schedule I controlled substance in the United States.<ref>Federal Register Vol. 80 No. 20, Friday January 30, 2015. "Schedules of Controlled Substances: Temporary Placement of Three Synthetic Cannabinoids Into Schedule I" (GPO.gov) | https://www.gpo.gov/fdsys/pkg/FR-2015-01-30/pdf/2015-01776.pdf</ref>
*'''United Kingdom:''' AB-CHMINACA is a class B drug under the third-generation synthetic cannabinoids generic definition, which came into effect on the 14th December 2016. It is illegal to possess, produce, supply, or import. <ref>The Misuse of Drugs Act 1971 (Amendment) Order 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2016/1109/made</ref>
*'''China:''' As of October 2015 AB-CHMINACA is a controlled substance in China.<ref>关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref>
*'''United States:''' In January 2015, AB-CHMINACA was designated as a Schedule I controlled substance in the United States.<ref>Federal Register Vol. 80 No. 20, Friday January 30, 2015. "Schedules of Controlled Substances: Temporary Placement of Three Synthetic Cannabinoids Into Schedule I" (GPO.gov) | https://www.gpo.gov/fdsys/pkg/FR-2015-01-30/pdf/2015-01776.pdf</ref>
 


==See also==
==See also==
Return to "AB-CHMINACA" page.